[HTML][HTML] Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial …
JAC Sterne, PN Bodalia, PA Bryden… - Health Technology …, 2017 - pmc.ncbi.nlm.nih.gov
BACKGROUND Warfarin is effective for stroke prevention in atrial fibrillation (AF), but
anticoagulation is underused in clinical care. The risk of venous thromboembolic disease …
anticoagulation is underused in clinical care. The risk of venous thromboembolic disease …
New oral anticoagulants in elderly patients with atrial fibrillation
PC Deedwania - The American journal of medicine, 2013 - Elsevier
The prevalence of atrial fibrillation increases with age, augmenting the risk of embolic stroke
in elderly individuals. Clinical practice guidelines recommend the long-term use of oral …
in elderly individuals. Clinical practice guidelines recommend the long-term use of oral …
[HTML][HTML] Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation
J Ferreira, A Mirco - Revista Portuguesa de Cardiologia (English Edition), 2015 - Elsevier
Abstract Introduction and Objectives Novel oral anticoagulants are emerging options for the
prevention and treatment of thromboembolic diseases. They are increasingly used in clinical …
prevention and treatment of thromboembolic diseases. They are increasingly used in clinical …
[HTML][HTML] The economic burden of ischemic stroke and major hemorrhage in medicare beneficiaries with nonvalvular atrial fibrillation: a retrospective claims analysis
K Fitch, J Broulette, WJ Kwong - American health & drug benefits, 2014 - ncbi.nlm.nih.gov
Background Understanding the economic implications of oral anticoagulation therapy
requires careful consideration of the risks and costs of stroke and major hemorrhage. The …
requires careful consideration of the risks and costs of stroke and major hemorrhage. The …
Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence
C Ferguson, SC Inglis, PJ Newton… - Vascular health and …, 2013 - Taylor & Francis
Atrial fibrillation is a common arrhythmia in heart failure and a risk factor for stroke. Risk
assessment tools can assist clinicians with decision making in the allocation of …
assessment tools can assist clinicians with decision making in the allocation of …
Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs
TI Verhoef, WK Redekop, RMF Van Schie… - …, 2012 - Taylor & Francis
Genotyping patients for CYP2C9 and VKORC1 polymorphisms can improve the accuracy of
dosing during the initiation of anticoagulation with vitamin K antagonists (coumarin …
dosing during the initiation of anticoagulation with vitamin K antagonists (coumarin …
Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly
KC Ogbonna, SM Jeffery - Drugs & aging, 2013 - Springer
The objective of this review was to compare the safety and efficacy of dabigatran,
rivaroxaban and apixaban to warfarin for the management of atrial fibrillation (AF) in older …
rivaroxaban and apixaban to warfarin for the management of atrial fibrillation (AF) in older …
[HTML][HTML] Revisão sistemática das análises custo‐efetividade dos novos anticoagulantes orais na prevenção do acidente vascular cerebral na fibrilhação auricular
J Ferreira, A Mirco - Revista Portuguesa de Cardiologia, 2015 - Elsevier
Introdução e objetivos Os novos anticoagulantes orais são opções emergentes para a
prevenção e tratamento das doenças tromboembólicas. São cada vez mais usados na …
prevenção e tratamento das doenças tromboembólicas. São cada vez mais usados na …
Anticoagulation control and cost of monitoring of older patients on chronic warfarin therapy in three settings in North East England
S Abohelaika, F Kamali, P Avery, B Robinson… - Age and …, 2014 - academic.oup.com
Background: novel oral anticoagulants may be particularly cost-effective when INR control
(TTR) with warfarin is poor or monitoring difficult. Setting: the Newcastle upon Tyne …
(TTR) with warfarin is poor or monitoring difficult. Setting: the Newcastle upon Tyne …
The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Mexico from a collective perspective
JB Briere, K Bowrin, R Wood, T Holbrook… - Journal of Medical …, 2017 - Taylor & Francis
Aims: To describe the collective costs of vitamin K antagonist (VKA) treatment for stroke
prevention in non-valvular atrial fibrillation (NVAF). VKA drug costs are relatively low, but …
prevention in non-valvular atrial fibrillation (NVAF). VKA drug costs are relatively low, but …